Inotiv posted preliminary Q4 FY2025 revenue of $137.5–138.5 million and full-year FY2025 revenue of $512.5–513.5 million, alongside a Discovery and Safety Assessment book-to-bill of approximately 1.08x in the quarter and 1.05x for the year. The DSA backlog edged up to roughly $138 million at September 30, 2025, up from $129.9 million a year earlier and $134.3 million at June 30. The company also reset its Jefferies Global Healthcare Conference presentation to November 18 at 11:00 a.m. GMT in London.
The signal beneath the numbers is a market that has stabilized and is inching forward. A book-to-bill hovering just above 1.0 and a growing backlog point to steady, not frothy, demand for preclinical services. The standout data point is DSA’s 60% year-over-year growth in the quarter, suggesting either market share gains or the release of pent-up demand from earlier bottlenecks. The strategic question for sponsors and CRO competitors alike is whether this momentum is durable or simply a favorable comparison against a softer 2024 base.
For biopharma Commercial and Medical Affairs leaders, this matters because preclinical capacity and predictability cascade into downstream launch and evidence timelines. Sponsors planning 2026–2027 INDs, Phase 1 starts, and early RWE scaffolding rely on dependable GLP tox windows and analytical throughput to hit development gates. A book-to-bill above 1.0 implies slightly tightening capacity; slot allocation and pricing discipline could follow. For payers and HCPs, the indirect impact is the cadence of new entrants, particularly in high-velocity categories like cardiometabolic and oncology, where preclinical throughput determines how quickly new mechanisms reach the clinic and, ultimately, practice.
The backdrop is a CRO sector that has been recalibrating after the pandemic-era surge, with biotechs now funding fewer, higher-conviction programs as the financing window selectively reopens. Sponsors are also testing alternative-to-animal methods—computational tox, organ-on-chip, and high-content in vitro—yet real-world demand for traditional DSA remains resilient, especially for large and complex modality packages and regulated submissions. Non-human primate supply constraints that disrupted timelines across the industry have moderated but not disappeared, keeping pressure on scheduling and cost. In this environment, CROs capturing sustained DSA growth while expanding analytical and research model capabilities will be positioned to win multiyear, cross-functional workstreams that bundle discovery, safety, bioanalysis, and model supply.
For competitors, Inotiv’s trajectory hints at a more rational pricing environment where utilization improves before aggressive rate expansion returns. For sponsors, the operational takeaway is tactical: lock in GLP tox and specialty model work early, bundle assays to secure priority resourcing, and push for digital transparency on study milestones to de-risk downstream protocol amendments and evidence plans. Medical Affairs teams should anticipate earlier coordination with nonclinical partners to shape biomarker strategies and external education narratives that will matter once first-in-human data emerges.
The next proof point will be the conversion of the $138 million backlog into revenue without margin slippage and whether DSA book-to-bill can stay north of 1.0 through mid-2026. If the sector continues this measured climb, will CROs tilt toward targeted capacity additions and selective M&A, or does the first broad biotech funding upswing trigger another scramble for scale and drive-time, reigniting the capacity cycle?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
